Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Adoptive cell therapy
BAT
BiTE
Bispecific T cell engager
Bispecific antibody
Bispecific antibody armed T cell
CAR T
Chimeric antigen receptor
Immunotherapy
Multiple myeloma
Stem cell transplantation
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
07 06 2022
07 06 2022
Historique:
received:
07
04
2022
accepted:
22
05
2022
entrez:
7
6
2022
pubmed:
8
6
2022
medline:
10
6
2022
Statut:
epublish
Résumé
Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of patients worldwide. Despite all the efforts to understand its pathogenesis and develop new treatment modalities, MM remains an incurable disease. Novel immunotherapies, such as CAR T cell therapy (CAR) and bispecific T cell engagers (BiTE), are intensively targeting different surface antigens, such as BMCA, SLAMF7 (CS1), GPRC5D, FCRH5 or CD38. However, stem cell transplantation is still indispensable in transplant-eligible patients. Studies suggest that the early use of immunotherapy may improve outcomes significantly. In this review, we summarize the currently available clinical literature on CAR and BiTE in MM. Furthermore, we will compare these two T cell-based immunotherapies and discuss potential therapeutic approaches to promote development of new clinical trials, using T cell-based immunotherapies, even as bridging therapies to a transplant.
Identifiants
pubmed: 35672793
doi: 10.1186/s13045-022-01296-2
pii: 10.1186/s13045-022-01296-2
pmc: PMC9171942
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
78Informations de copyright
© 2022. The Author(s).
Références
Mol Ther Methods Clin Dev. 2020 Jan 16;17:359-368
pubmed: 32071928
Front Oncol. 2020 Jul 23;10:1182
pubmed: 32793488
Lancet Haematol. 2020 Jun;7(6):e456-e468
pubmed: 32359506
Cells. 2020 May 09;9(5):
pubmed: 32397414
Nature. 2022 Feb;602(7897):503-509
pubmed: 35110735
Front Immunol. 2020 Aug 28;11:2109
pubmed: 32983169
Gene Ther. 2021 Sep;28(9):513-527
pubmed: 33753909
Blood Cancer J. 2021 Apr 6;11(4):69
pubmed: 33824268
Eur J Haematol. 2020 Aug;105(2):203-215
pubmed: 32289184
Blood Adv. 2021 Jan 26;5(2):607-612
pubmed: 33496755
Blood. 2019 Nov 7;134(19):1585-1597
pubmed: 31558469
Immunotherapy. 2015;7(11):1187-99
pubmed: 26370838
Haematologica. 2021 Apr 01;106(4):1193-1197
pubmed: 32675220
Nat Med. 2017 Dec;23(12):1436-1443
pubmed: 29106400
J Immunother Cancer. 2020 May;8(1):
pubmed: 32474415
Clin Transl Immunology. 2019 May 11;8(5):e1049
pubmed: 31110702
Blood Rev. 2021 Sep;49:100808
pubmed: 33863601
Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7021-5
pubmed: 7624362
Cancers (Basel). 2020 Apr 10;12(4):
pubmed: 32290052
Cancers (Basel). 2021 Apr 22;13(9):
pubmed: 33922005
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8
pubmed: 2513569
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):272-279
pubmed: 33275747
Hum Gene Ther. 2021 Jul;32(13-14):744-760
pubmed: 33554732
Blood Adv. 2019 Nov 12;3(21):3248-3260
pubmed: 31698455
Mol Ther Oncolytics. 2016 May 18;3:16014
pubmed: 27231717
Cancers (Basel). 2021 Apr 02;13(7):
pubmed: 33918370
Blood Cancer J. 2021 Jun 18;11(6):116
pubmed: 34145225
Clin Cancer Res. 2019 Jul 1;25(13):3921-3933
pubmed: 30918018
Nature. 2017 Mar 2;543(7643):113-117
pubmed: 28225754
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
J Clin Oncol. 2020 Mar 10;38(8):775-783
pubmed: 31895611
Leuk Lymphoma. 2002 Mar;43(3):613-6
pubmed: 12002767
Asian Pac J Cancer Prev. 2015;16(7):3079-81
pubmed: 25854409
Clin Cancer Res. 2008 May 1;14(9):2775-84
pubmed: 18451245
Mol Ther. 2019 Jun 5;27(6):1126-1138
pubmed: 31005597
Front Immunol. 2020 Feb 26;11:326
pubmed: 32194561
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):260-265
pubmed: 31808895
Blood Cancer Discov. 2021 Jul;2(4):302-318
pubmed: 34386775
Blood. 2018 Feb 15;131(7):746-758
pubmed: 29284597
J Hematol Oncol. 2020 Jul 2;13(1):86
pubmed: 32616000
Hum Gene Ther. 2019 Feb;30(2):168-178
pubmed: 30024272
Chronic Dis Transl Med. 2021 Aug 31;7(4):220-226
pubmed: 34786541
Front Oncol. 2020 Jul 28;10:1243
pubmed: 32850376
Sci Transl Med. 2019 Mar 27;11(485):
pubmed: 30918115
Front Immunol. 2018 Feb 19;9:239
pubmed: 29515572
Nat Med. 2019 Sep;25(9):1341-1355
pubmed: 31501612
Assay Drug Dev Technol. 2021 Jan;19(1):17-26
pubmed: 33232610
Blood. 2011 Jun 9;117(23):6202-13
pubmed: 21474670
Immunity. 2016 Jun 21;44(6):1444-54
pubmed: 27332733
Eur J Clin Invest. 2012 Sep;42(9):953-60
pubmed: 22591013
Haematologica. 2005 Apr;90(4):489-93
pubmed: 15820944
Blood. 1990 Jul 15;76(2):377-82
pubmed: 1695113
J Clin Invest. 2019 Mar 21;129(6):2210-2221
pubmed: 30896447
Front Immunol. 2020 May 07;11:762
pubmed: 32457743
Leukemia. 2020 Jan;34(1):180-195
pubmed: 31358854
Mol Cancer Ther. 2012 Oct;11(10):2222-32
pubmed: 22807577
Clin Cancer Res. 2013 Apr 15;19(8):2048-60
pubmed: 23344265
Curr Issues Mol Biol. 2022 Mar 24;44(4):1463-1471
pubmed: 35723356
Iran J Cancer Prev. 2015 Oct;8(5):e3755
pubmed: 26634107
Am J Manag Care. 2021 Aug;27(13 Suppl):S253-S261
pubmed: 34407361
Front Oncol. 2020 May 05;10:544
pubmed: 32432032
J Clin Oncol. 2018 Aug 1;36(22):2267-2280
pubmed: 29812997
J Immunother Cancer. 2021 Dec;9(12):
pubmed: 34876408
EBioMedicine. 2020 Aug;58:102931
pubmed: 32739874
J Hematol Oncol. 2021 May 3;14(1):75
pubmed: 33941237
Ann Oncol. 2021 Mar;32(3):309-322
pubmed: 33549387
Nat Commun. 2015 Jun 11;6:7333
pubmed: 26065893
Haematologica. 2016 May;101(5):616-25
pubmed: 26858358
Front Immunol. 2021 Feb 25;12:552429
pubmed: 33717057
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669947
Front Immunol. 2021 Mar 05;12:609421
pubmed: 33767695
Gene Ther. 2021 Feb;28(1-2):3-5
pubmed: 32139891
Am J Clin Pathol. 2004 Feb;121(2):254-63
pubmed: 14983940
Nat Rev Clin Oncol. 2022 May;19(5):342-355
pubmed: 35318469
Front Immunol. 2018 Mar 08;9:441
pubmed: 29568297
Nat Commun. 2020 Nov 27;11(1):6080
pubmed: 33247092
J Immunol. 2000 Dec 1;165(11):6047-55
pubmed: 11086036
Nat Commun. 2021 Dec 10;12(1):7200
pubmed: 34893603
Front Oncol. 2020 Aug 05;10:1362
pubmed: 32850436
J Clin Med. 2020 Nov 06;9(11):
pubmed: 33172026
Front Med (Lausanne). 2021 May 07;8:649824
pubmed: 34026784
EBioMedicine. 2020 Sep;59:102975
pubmed: 32853984
Immunotargets Ther. 2021 Jul 16;10:247-260
pubmed: 34295843
Oncotarget. 2018 Mar 27;9(23):16557-16572
pubmed: 29662667
Oncotarget. 2018 May 25;9(40):25764-25780
pubmed: 29899820
JCI Insight. 2019 Apr 4;4(7):
pubmed: 30944260
Leukemia. 2021 Mar;35(3):752-763
pubmed: 32632095
Int J Mol Sci. 2019 Mar 14;20(6):
pubmed: 30875739
Med Sci (Basel). 2021 Jan 20;9(1):
pubmed: 33498356
J Hematol Oncol. 2018 Dec 20;11(1):141
pubmed: 30572922
Mol Ther. 2017 Oct 4;25(10):2270-2279
pubmed: 28757080
Methods Mol Biol. 2020;2086:119-130
pubmed: 31707671
Mol Cancer. 2019 Nov 5;18(1):154
pubmed: 31684964
Methods Mol Biol. 2020;2086:131-137
pubmed: 31707672
Ann Med. 2021 Dec;53(1):1547-1559
pubmed: 34459681
Sci Transl Med. 2020 Mar 11;12(534):
pubmed: 32161106